Form 4: BioMarin Director Athena Countouriotis Reports Acquisition of Restricted Stock Units

Athena Countouriotis, a director at BioMarin Pharmaceutical Inc., reported the acquisition of 4,720 restricted stock units on May 21, 2024.

Summary

• On May 23, 2024, Athena Countouriotis, a director of BioMarin Pharmaceutical Inc., filed a Form 4 with the SEC.
• The report details a transaction on May 21, 2024, where Ms. Countouriotis acquired 4,720 shares of common stock in the form of restricted stock units.
• These restricted stock units were granted at a price of $0.
• Following the transaction, Ms. Countouriotis directly owns 6,900 shares of BioMarin common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock units granted to a director. It suggests confidence but doesn't provide strong positive or negative signals.

Positives

• The acquisition of restricted stock units by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates changes in the holdings of a BioMarin director.

Stakeholder Impact

• The acquisition of restricted stock units by a director may have a slightly positive impact on shareholder sentiment.

Key Dates